RxDoctor Payments Data

Johnna Bridges, PA

Physician Assistant · Valdosta, GANPI 1114007424

Payments from drug & device makers

$3,988in general payments, 2019–2025

Across 149 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Dendreon Pharmaceuticals LLC$367
  • Astellas Pharma US Inc$367
  • Endo Pharmaceuticals Inc.$290
  • Johnson & Johnson$270
  • Antares Pharma, Inc.$250
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$70518%
  • Food & beverage$2,80770%
  • Education$47612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,988 in reported general payments places this provider in the 85th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$19,563
Medicare patients
110
Services billed
461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron188$110,188
GemtesaVibegron45$36,611
XyostedTestosterone Enanthate22$14,918
Methenamine Hippurate174$13,423
Dutasteride259$7,980
Tamsulosin Hcl391$5,471
PremarinEstrogens, Conjugated12$5,436
Potassium Citrate ErPotassium Citrate50$4,797
Fesoterodine Fumarate ErFesoterodine Fumarate16$3,282
Testosterone18$2,807
Silodosin40$2,786
Trospium Chloride20$1,927
Alfuzosin Hcl ErAlfuzosin Hcl96$1,788
Estradiol16$1,520
Finasteride126$1,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$367$110,188188 claims
Sumitomo Pharma America, Inc.Gemtesa$136$36,61145 claims
Antares Pharma, Inc.Xyosted$250$14,91822 claims
PfizerPremarin$131$5,43612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →